glp 1 compounding ban New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA is moving to restrict

As mentioned above, the two main identified proteases for the degradation of GLP-1 in vivo are DPP-4 and NEP-24.11

Moreover, the SURMOUNTMMO (tirzepatide, NCT05556512) will assess the impact of the dual GLP-1/GIP RA in cardiovascular outcomes and all-cause mortality for people with obesity (without diabetes) when the REDEFINE-3 study will assess the impact of cagrisema in people with obesity (with and without T2DM) and established cardiovascular disease

The report also discusses safety controversies (such as past concerns about pancreatitis and thyroid tumors) and how they have been addressed by research and regulatory reviews

Semaglutide has also demonstrated cardiovascular benefits in people with overweight or obesity and established cardiovascular disease